March 3rd, 2021: Myelo Therapeutics Expands NIH-NIAID Collaboration and Joins Bayer Pharmaceuticals Incubator
June 26th, 2020: Myelo Therapeutics Closes Financing Round and Gains Strong Backing of Eckert & Ziegler Group.
May 11th, 2020: Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million for Development of Myelo001 as Treatment for Acute Radiation Syndrome.
Nov 4th, 2019: New data confirming Myelo001 efficacy in Acute Radiation Syndrome presented at 65th annual meeting of the Radiation Research Society.
July 24th, 2019: EMA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.
Dec 4th, 2018: Positive Data on Efficacy of Myelo001 in treating Acute Radiation Syndrome published in Blood.
Sep 25th, 2018: FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.
March 1st, 2018: Myelo Therapeutics has been selected as a finalist of the Lyfebulb-Helsinn Innovation Summit Award in Oncology..
Nov 8th, 2017: Interview on progress of Myelo001 development program and Myelo Therapeutics experience with Elsevier’s “The Hive” incubator program.
Oct 4th, 2017: Myelo Therapeutics’ Phase II study of Myelo001 in Chemotherapy-induced Neutropenia is fully recruited.
June 20th, 2017: Myelo Therapeutics conducts successful Pre-IND meeting with U.S. Food and Drug Administration (FDA) for Myelo001 and completes new financing round.
Jan 16th, 2017: New data published in Blood confirms that the chemo-protective effect of Myelo001 is specific to healthy tissue.
Jan 13th, 2017: Myelo Therapeutics is selected as one of four companies worldwide to participate in Elsevier's incubator project.